Article Text

PDF
Pharmacological interventions
Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression
  1. Chittaranjan Andrade
  1. Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India; andradec@gmail.com

Statistics from Altmetric.com

ABSTRACT FROM: Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015;76:e487–98.

What is already known on this topic?

Several strategies have been proposed for patients with treatment-resistant depression (TRD), including dose optimisation, switching to another therapeutic class or combination/augmentation regimens,1 however, it is still not known how the different strategies compare with each other. Zhou and colleagues specifically examined augmentation strategies for efficacy and acceptability in a network meta-analysis of randomised controlled trials (RCTs).

Methods of the study

PubMed, the Cochrane Library, clinical trial registries and drug company websites were searched for published/unpublished RCTs comparing augmentation strategies (or placebo) for the acute treatment of adults with TRD (defined as major depressive disorder with previous failure and current non-response to at least one oral, first-line, therapeutically dosed antidepressant drug). Original study authors and drug manufacturers were contacted. RCTs …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.